REFLECT SCIENTIFIC, INC.
RSCF · Healthcare · $3.4M mkt cap · FY2023 filings · Shallow moat ·
Doesn't clear the bar
The five investor questions
2017–2023: revenue 1065777.00 to 1080154.00, increasing; diluted EPS -0.01 to -0.01, flat. 1 fiscal year was not jointly reported; CAGR uses the full 6-year elapsed span.
Median gross margin 61.6% over 10y, very stable.
Median ROIC -59.6%, above the 12% hurdle in 25% of years.
Net cash position — no leverage risk.
Owner earnings trend unclear, share count growing (dilution).
Price vs. owner-earnings value range
- Owner earnings (normalized)
- $89396
- Value range / share
- $0.01–$0.01
- Conservative high estimate / share
- $0.01
- Recent price
- $0.04
- Price vs. high estimate
- 245% above high estimate
Conservative range under moat-index@2.0.0: low end 11.1×, high end capped at 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
15 years of fundamentals
The business, in plain English
REFLECT SCIENTIFIC, INC. booked $1.1M of revenue in FY2023 in the Healthcare sector and kept 55.2% of it as gross profit — a high-margin business by that measure. After every other cost, −42.5% of each revenue dollar reached the bottom line.
Across the filed record, revenue shrank from $2.4M (FY2010) to $1.1M (FY2023) — about −6.0% a year compounded over 13 years.
It earned −60.1% on invested capital in FY2023, with a median of −59.1% across 9 filed years. The Returns on Capital filter above scores it 9/100.
RSCF's filings don't disclose total debt in a form the methodology can use, so leverage is treated as unmeasured — never assumed to be zero.
The share count rose 143.2% between FY2009 and FY2023 — existing owners have been diluted over the record. Capital Discipline scores it 24/100.
Put together: Pricing Power is the strongest of the five filters (94/100) and Returns on Capital the weakest (9/100), which is how RSCF lands at 43/100 — a Shallow moat.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Gaps in a line mean that item isn’t in RSCF’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Moat Score history
Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.
Track record
How REFLECT SCIENTIFIC, INC.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.
How to read this: each dot is what the engine would have scored RSCF on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.
Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.
What followed, in the years it rated Wide
In the reconstructed history shown, RSCF did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.
Healthcare context
#300 of 736 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #298MGRX MANGOCEUTICALS, INC.43.4 out of 100, Shallow moatShallow moat
- #299LFMD LIFEMD, INC.43.3 out of 100, Shallow moatShallow moat
- #301NXL NEXALIN TECHNOLOGY, INC.43.2 out of 100, Shallow moatShallow moat
- #302FBIO Fortress Biotech, Inc.43.1 out of 100, Shallow moatShallow moat
Compare RSCF with its nearest peers →All Healthcare companies on the Index →
Common questions about RSCF
- Does REFLECT SCIENTIFIC, INC. have an economic moat?
- Based on its FY2023 SEC filings, the Moat Index scores REFLECT SCIENTIFIC, INC. (RSCF) 43.3 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 34, pricing power 94, returns on capital 9, balance-sheet safety 55, capital discipline 24.
- Is RSCF trading below the conservative owner-earnings estimate?
- The owner-earnings value range is $0.01–$0.01 per share. It capitalizes normalized owner earnings at a 9% rate; the low end assumes 0% growth and the high end uses 0% growth, capped at 4% and 18×. Versus a recent price of $0.04, that is 245% above high estimate relative to the high estimate. This is a conservative educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.
- How has RSCF's Moat Score changed over time?
- The record logs 8 readings since Jul 17, 2026; the latest reads 43.3 out of 100 (shallow moat). No tier changes on record yet. (A methodology upgrade on Jul 20, 2026 re-based the score; readings across engine versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.